OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

Oxford Cannabinoid Technologies Holdings Plc

Equities

OCTP

GB00BMVMRB86

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 06:46:31 28/05/2024 pm IST			5-day change	1st Jan Change
0.193 ^GBX	-5.85%		+10.29%	-69.12%

17/05	Oxford Cannabinoid says it remains bound by Takeover Code	AN
08/05	Oxford Cannabinoid shares plummet following delisting request	AN

IN BRIEF: Oxford Cannabinoid CEO steps down to pursue other interests

December 05, 2022 at 10:06 pm IST

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical firm developing prescription cannabinoid medicines - Announces that Chief Executive John Lucas has decided to step down from his role "in order to pursue other business interests."

Current Chief Operating Officer Clarissa Sowemimo-Coker will take over as CEO on an interim basis while the company completes its phase one clinical trials for its lead OCT461201 programme. This is due to begin in January, with results expected early in the second quarter of 2023. OCT461201 is being tested for both neuropathic and visceral pain.

Current stock price: 0.59 pence

12-month change: down 79%

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Oxford Cannabinoid Technologies Holdings Plc

Oxford Cannabinoid says it remains bound by Takeover Code	18/05	AN
Oxford Cannabinoid shares plummet following delisting request	08/05	AN
Oxford Cannabinoid Technologies Files for Delisting From London Bourse	08/05	MT
Oxford Cannabinoid teams with iNGENu to test OCT130401 pain treatment	11/04	AN
Oxford Cannabinoid Technologies Holdings plc Appoints Timothy Henry Corn as A Director	09/04	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Lord Darren James Mott as Director	08/04	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Lord Mott OBE as an Independent Non-Executive Director	29/02	CI
Oxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024	29/02	CI
Oxford Cannabinoid completes capital reorganisation	16/02	AN
Oxford Cannabinoid Technologies Concludes Capital Reorganization	16/02	MT
Oxford Cannabinoid Technologies Completes Equity Raise	15/02	MT
Oxford Cannabinoid shares up on applying to admit new shares	15/02	AN
Oxford Cannabinoid applies for new shares to be listed	15/02	AN
Oxford Cannabinoid Technologies Applies for Admission of Redenominated Shares on London Bourse	14/02	MT
Oxford Cannabinoid Technologies Enters Convertible Loan Note Agreements	02/02	MT
Oxford Cannabinoid agrees GBP565,000 loan notes deal	02/02	AN
Oxford Cannabinoid Technologies to Raise GBP1.2 Million via Subscriptions, Investment; Shares Plunge	30/01	MT
Oxford Cannabinoid Technologies down after GBP1.2 million fundraise	30/01	AN
Oxford Cannabinoid Technologies Holdings Plc Reports Earnings Results for the Half Year Ended October 31, 2023	30/01	CI
Oxford Cannabinoid Technologies Files Patent for New Cannabinoid Compound in Europe	10/01	MT
Oxford Cannabinoid stock goes high on Europe patent filing	10/01	AN
Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2	10/01	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive Director	14/11	CI
Kingsley Capital reduces stake in Oxford Cannabinoid	20/23/20	AN
Oxford Cannabinoid Technologies Completes Dosing in Phase 1 Study for Lead Drug Candidate	10/23/10	MT

Chart Oxford Cannabinoid Technologies Holdings Plc

Duration

Period

Chart Oxford Cannabinoid Technologies Holdings Plc

More charts

Company Profile

Oxford Cannabinoid Technologies Holdings plc is a United Kingdom-based pharmaceutical company developing prescription cannabinoid medicines. The Company is working with three types of cannabinoid compounds: synthesized phytocannabinoids, cannabinoid derivatives and novel chemical entities. Its drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and other therapeutic areas. It has a portfolio of four drug development programs: Program 1 (OCT461201), Program 2 (OCT130401), Program 3 (Cannabinoid derivative) and Program 4 (Cannabinoid derivative). Its OCT461201 is a new chemical entity, CB2 receptor agonist, chemically synthesized to behave like a cannabinoid. Its OCT130401 is a drug/device combination. It has a portfolio of over 500 derivatives and intellectual property rights, including 14 patent families and associated research data.

Sector

Biotechnology & Medical Research

Calendar

09/10/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC	-69.12%	28.5L
MODERNA, INC.	+67.53%	6.39TCr
IQVIA HOLDINGS INC.	-0.77%	4.18TCr
LONZA GROUP AG	+42.32%	4.05TCr
CELLTRION, INC.	-10.02%	2.72TCr
ICON PUBLIC LIMITED COMPANY	+13.30%	2.65TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	1.87TCr
BIO-TECHNE CORPORATION	+4.70%	1.27TCr
UNITED THERAPEUTICS CORPORATION	+24.10%	1.21TCr
MEDPACE HOLDINGS, INC.	+27.41%	1.21TCr

Other Biotechnology & Medical Research

Oxford Cannabinoid Technologies Holdings Plc

Equities

OCTP

GB00BMVMRB86

Biotechnology & Medical Research

IN BRIEF: Oxford Cannabinoid CEO steps down to pursue other interests

Latest news about Oxford Cannabinoid Technologies Holdings Plc

Chart Oxford Cannabinoid Technologies Holdings Plc

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research